1/6/2009

Cubist Pharmaceuticals asked the FDA to allow clinical studies of two treatments for bacterial infections. Cubist said it is developing two lipopeptides -- CB-182,804 for drug-resistant Gram-negative bacteria and CB-183,315 for diarrhea linked to Clostridium difficile.

Related Summaries